Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 19,865 shares of common stock in open-market transactions. The sales occurred on April 10, 13, and 14, 2026 at weighted average prices of $34.98, $34.97, and $35.08 per share, respectively. According to the filing, these trades were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following the last sale, he continues to directly own 266,651 shares of Rapport Therapeutics common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 notice relating to the proposed sale of Common shares connected with an affiliate account. The filing lists three 10b5-1 sales by KRISHNASWAMY: 10,115 shares on 03/25/2026, 360 shares on 04/08/2026, and 500 shares on 04/10/2026, with dollar amounts shown alongside each transaction. The cover block includes a figure of 47,792,943 shares as of 04/13/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 disclosing proposed sales of 500 shares of Common Stock by a holder and recent 10b5-1 dispositions by Krishnaswamy. The filing lists 10b5-1 sales of 360 shares for $12,564.00 (04/08/2026) and 10,115 shares for $303,354.24 (03/25/2026).
Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares of Common Stock in an open-market transaction at $34.90 per share on April 8, 2026.
After this sale, he directly holds 286,516 shares of Rapport Therapeutics Common Stock. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was pre-arranged.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice listing proposed sales of 360 shares of Common stock. The filing also records 10b5-1 sales of 10,115 shares on 03/25/2026 for $303,354.24. The excerpt shows 47,792,943 shares outstanding as of 04/08/2026.
Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported selling a total of 10,000 shares of Common Stock in open-market transactions. She sold 7,161 shares at a weighted average price of $28.0401 and 2,839 shares at a weighted average price of $28.5530. After these sales, she directly holds 159,914 shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sales were scheduled in advance rather than timed discretionarily.
RAPP submitted a Rule 144 notice listing a proposed sale of 10,000 shares of Common stock. The filing shows a value of $278,400.00 and references Cheryl Gault with an address on the filing. Dates shown include 09/05/2024 and 03/30/2026.
Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of common stock in an open-market transaction at a weighted average price of $29.9906 per share. The shares were sold in multiple trades between $29.90 and $30.18.
After this sale, Krishnaswamy directly holds 286,876 shares of Rapport Therapeutics common stock. The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sale was scheduled in advance.
RAPP filed a Form 144 reporting proposed resale activity in its Common Stock. The filing lists an offering date of 05/20/2025 and a filing marker of 03/25/2026. The excerpt shows a reported sale of 2,840 Common shares on 12/31/2025 for $85,342.